Recursion Pharmaceuticals (RXRX) shares plunged 16.6% on Sept. 3 after announcing mixed results from a mid-stage study evaluating the safety, tolerability and efficacy of its lead candidate, REC-994, an orally bioavailable, superoxide scavenger small molecule, for symptomatic cerebral cavernous malformation (CCM) patients.Recursion’s SYCAMORE Study Meets Primary Goal but Efficacy LagsRecursion reported that its phase II SYCAMORE study met the primary endpoint of safety and tolerability in CCM patients treat ...